Fund moves
63 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 1, 2026 · Filed May 4, 2026
A Regeneron Pharmaceuticals director sold $11K of Regeneron Pharmaceuticals shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$10,537
Shares × reported transaction price
2 days after results of Apr 29, 2026, 66 days before results of Jul 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $701.42 on May 1, 2026, 45% above its 52-week low and 14% below its high, after a 5% drop over the previous 30 trading days
52-week range $483.07 (Jun 5, 2025) to $812.27 (Jan 7, 2026), 66% of the way up, from 251 adjusted closes. 30 trading days earlier: $737.45 on Mar 19, 2026. Describes the past only, not a forecast
RSI 37, 3% above its 200-day average, 7% under its 50-day average, 14% below the 52-week high, 20-day volatility 32% a year, against the S&P 500: −20 points over 1 month, −10 points over 3 months, +3 points over 6 months
From the adjusted closes up to May 1, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Dupixent on Apr 22, 2026, 9 days before this trade.
New use approved (efficacy supplement). Active ingredient: Dupilumab. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.0% | +2.0% | +1.0% |
| 30 days | −10.5% | +4.6% | −15.1% |
| 90 days | +8.1% | +4.7% | +3.4% |
| 180 days | +36.9% | +3.9% | +33.0% |
Past results only. Not a forecast.
Fund moves
63 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
66 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
63 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.